Navigation Links
IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamurtide (L-MTP-PE)
Date:6/2/2008

- Data Presented at the 44th American Society for Clinical Oncology (ASCO)

Annual Meeting -

IRVINE, Calif., June 2 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced the presentation of an analysis from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). The results suggest that the addition of L-MTP-PE to chemotherapy improved overall survival with a 25% reduction in the risk of death in newly diagnosed patients with metastatic osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults.

"These data in a difficult-to-treat metastatic patient population are encouraging, especially given the limited treatment options available," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "We continue to believe the data from non-metastatic patients in the L-MTP-PE Phase 3 study warrants regulatory approval in Europe and the United States and are optimistic that the overall survival benefit seen with L-MTP-PE will be the clinical evidence needed to support bringing this important treatment to market."

The Phase 3 L-MTP-PE trial (INT-0133) is National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG) and is the largest study completed in osteosarcoma, enrolling approximately 800 patients. The multicenter, open label, randomized, factorial, four parallel treatment group Phase 3 study was designed to evaluate patient outcomes with the addition of L-MTP-PE to adjuvant three- or four-drug chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide).

The analysis evaluated 91 newly diagnosed patients with metastatic osteosarcoma who
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Managing Cross-Functional Teams for Pharmaceutical Product Commercialization Excellence
2. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
3. KV Pharmaceutical Company Updates Timing of Fiscal 2008 Securities and Exchange Commission Filings
4. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
5. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
6. Meijer Pharmacies to Offer Free Pre-Natal Vitamins
7. Sun Pharma Responds to Taros Purported Termination of Merger Agreement
8. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
9. FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management
10. Research Study Shows That Pharmaceutical Field Sales Reps Productivity Inhibited by Unnecessary Internal Communication
11. China Pharma Holdings, Inc. Enters Into Private Placement Agreements to Raise $10 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... a famous bamboo flooring company offering bamboo flooring products ... its multiple layer bamboo panel board collection , and ... Bamboo panel is the product made from 100 percent ... features high quality selective bamboo and eco-friendly adhesives that ... consists of multiple layers of bamboo. , According to ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... News) -- A new, injectable weight-loss drug has been ... The agency on Tuesday approved Saxenda (liraglutide) for adults ... and have at least one weight-related health condition, such ... cholesterol. Patients taking the drug, made by Novo ... regularly, the FDA noted. "Obesity is a public ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Researchers say ... cells that develop into eggs and sperm. While ... this is the first time that these types of ... produced efficiently using human stem cells, according to the ... "The creation of primordial germ cells is one of ...
(Date:12/24/2014)... -- A lab technician with the U.S. Centers for ... the Ebola virus in an agency laboratory in Atlanta ... other lab workers are being checked for possible exposure, ... exposure occurred Monday when CDC scientists doing research on ... virus to another CDC lab in the same building, ...
Breaking Medicine News(10 mins):Health News:Bamboo Flooring Company Bambooindustry.com Introduces Its Multiple Layer Bamboo Panel Board Collection 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... MONDAY, Dec. 5 (HealthDay News) -- There,s been a large increase ... States since 2002, a trend that may help ease concerns about ... analyzed national data and found that the number of RNs aged ... fell to fewer than 110,000 by 1991 and remained low for ...
... University of Kentucky researchers recently received a $225,000 grant ... The grant gives the team $225,000 for the ... that could total $675,000. It is funded by the ... Rural Cancer Prevention Center. Published studies have shown ...
... By Serena Gordon HealthDay Reporter , MONDAY, Dec. ... with asthma is currently using a preventive medication, according to ... percent of kids during the late 1980s. Preventive ... up, and guidelines from the U.S. National Asthma Education and ...
... -- Teenagers with autism who also have epilepsy often ... The combination means that certain behaviors common among autistic ... of their faces -- could increase their risk for ... 14 percent of children with epilepsy, the rate jumps ...
... and non-obese children found that low vitamin D levels are ... risk factors for type 2 diabetes. This study was accepted ... Endocrinology & Metabolism (JCEM). High rates of vitamin ... studies have linked low vitamin D levels to cardiovascular disease ...
... , SATURDAY, Dec. 3 (HealthDay News) -- Seizures ... during menstruation or ovulation, researchers have found. ... at the University of California, Irvine, examined the trend ... among a group of women aged 19 to 50. ...
Cached Medicine News:Health News:Good News for Those Worried About U.S. Nursing Shortage 2Health News:University of Kentucky researchers awarded CDC grant to study cancer survival in Appalachia 2Health News:More Children Using Preventive Asthma Drugs: Study 2Health News:More Children Using Preventive Asthma Drugs: Study 3Health News:Low vitamin D levels may contribute to development of Type 2 diabetes 2Health News:Epileptic Seizures May Worsen During Menstrual Cycle 2
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... Sheets: SIMH)  In a shrewd execution of its business ... with Keith Houlihan, Co-founder and President of Sanomedics ... signing of a letter of intent to acquire a ... platform in sleep apnea treatment services.  The targeted acquisition ...
... Dec. 12, 2011  Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and infectious diseases, announced today that Dr. J. Joseph Kim, ... at the Oppenheimer 22nd Annual Healthcare Conference taking place December ... Inovio Presentation December 13 10:50 am ET ...
Cached Medicine Technology:Sanomedics Signs Letter of Intent to Acquire Large Sleep Disorder Service Based Operation 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3
... Cutter has application in multiple open or ... resection, and/or creation of anastomoses and can ... buttressing materials such as bovine pericardium., ... a total of eight firings. Different cartridges ...
... in Open Procedures with Compact Endoscopic ... Compact-Flex45 No-Knife Articulating Linear Staplers is ... line for open surgical procedures. It ... blue cartridge, a thick-tissue green cartridge, ...
... ENDO CLIP MultApplier reusable clip applier is designed ... loading unit, each of which contains eight (8) ... shaft of the instrument is approximately 12.8" (32.5 ... and use through an appropriately sized Auto Suture ...
ENDO CLIP II ML, 10 mm Pistol Grip Single Use Clip Applier with Medium - Large Super Interlock Titanium Clips...
Medicine Products: